The DNDi Indian office and the Indian Council of Medical Research (ICMR) organized a clinical experts meeting on lymphatic filariasis (LF). The meeting objectives were; to identify the unmet needs for the treatment of LF patients in Asia and; to define the target product profile (TPP) for LF case management in Asia.
Opening Session
Date: February 22 2016
Time: 09:00-10:30
| Welcome Suman Rijal, Director DNDi India office |
| The DNDi model and DNDi R&D Ooverview Graeme Bilbe, R&D Director, DNDi |
| DNDi filariasis programme objectives and meeting agenda Claudia Pena Rossi, Head, Filarial Program, DNDi |
| Indian Council of Medical Research (ICMR) activities on filariasis Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR |
| Opening Remarks A C Dhariwal, Director, National Vector Borne Disease Control Program Swarup Kumar Sarkar, Director Communicable Disease, WHO-SEARO Soumya Swaminathan , Director General, ICMR |
Session 1
Date: February 22 2016
Time: 10:45-12:30
Burden of LF in 2015 and estimated projections 2020-2025
| LF epidemiology and global control program Ahmed Jamsheed Mohamed, Medical Officer-VBN WHO Regional Office for South-East Asia |
| LF in India: Current burden and control program progress P K Srivastava, LF India National Program, NVBDCP |
| PacELF – Eliminating lymphatic filariasis in the Asia Pacific Kazuyo Ichimori, Professor, Institute of Tropical Medicine, Nagasaki University. |
| Projected LF prevalence (infection and morbidity) in 2020-2025 Dr. Wilma Stock, Senior Researcher/Epidemiologist. Erasmus MC University Medical Center Rotterdam |
| General discussions and conclusions on future burden of LF |
Session 2
Date: February 22 2016
Time: 13:30-15:15
LF pathogenesis, clinical manifestations and diagnosis in Asia
| Pathogenesis of LF V. Kumaraswami. Former Director of Tuberculosis Research center, Chennai, India. |
| Diagnosis Gary Weil. Professor, Washington University School of Medicine |
| Clinical manifestations and patient categories Suma TK. Prof of Internal Medicine, Medical College Hospital, Alappuzha, Kerala |
| General discussions and conclusion on patient subpopulations |
Session 3
Date: February 22 2016
Time: 15:30-16:00
LF treatment
| Efficacy of current treatments on LF morbidity Suma TK. Prof. of Internal Medicine. Medical College Hospital, Alappuzha, Kerala |
| Efficacy of current treatments on the parasite (micro and macrofilaricidal effect) K. Ramaiah Consultant LF |
Session 3
Date: February 22 2016
Time: 16:00-17:45
New treatments under investigation
| Preliminary results of current clinical trials on LF Gary Weil. Professor Washington University School of Medicine |
| Doxycycline effect on the LF parasites and on morbidity Alex Debrah. Parasitology lecturer at Kwame Nkrumah University of Science and Technology (KNUST) |
| Studies on new treatments on Filariasis in India Jambulingam, Scientist G & Director – Vector Control Research Centre |
| General discussions and conclusion on main efficacy gaps |
Session 4
Date: February 23 2016
Time: 09;:00-13:00
TPP for LF case management
| Patients perspective Mitali Mohanty from the LEPRA Society. Project director of the LF programme in Puri district, Odisha. |
| Presentation of the results of the survey done among physicians treating patients Thomas John, DNDi consultant |
| Questions |
| Introduction TPP (DNDi) Nathalie Strub-Wourgaft, Medical Director, DNDi |
| Defining the TPP Moderator panel 1: A. C. Dhariwal Director, National Vector Borne Disease Control Program (TBC) Moderator panel 2: Rashmi Arora, Head, Division of Epidemiology & Communicable Diseases, ICMR (TBC) |
| Conclusion Suman Rijal, Director, DNDi, India |
